Global Critical Care Antiarrhythmic Drugs Market
Number of pages: 100 | Report Format: PDF | Published date: January 18, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 958 million |
|
Revenue Forecast in 2030 |
US$ 1,511.84 million |
|
CAGR |
5.2% |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Drug class, Disease type, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global critical care antiarrhythmic drugs market was valued at US$ 958 million in 2021 and is expected to register a revenue CAGR of 5.2% to reach US$ 1511.84 million by 2030.
Global Critical Care Antiarrhythmic Drugs Market Fundamentals
An erratic heartbeat is referred to as a cardiac arrhythmia. When the electrical signals that control how often the heart beats are coordinated improperly, heart rhythm issues (heart arrhythmias) result. The heart beats excessively quickly (tachycardia), too slowly (bradycardia), or irregularly due to poor signaling. Some heart rhythms can result in discomfort and are potentially fatal. Having a fast or sluggish heart rate occasionally is natural. For instance, the heart rate may rise during physical activity or fall during sleep.
Supraventricular arrhythmia is characterized by an abnormal heart rate that begins above the ventricular, the heart's two lowest chambers. Most supraventricular arrhythmias start in the atria, the top chambers of the heart. They might make the heartbeat too quick, too slow, or erratic. There are different types of SVT (supraventricular tachycardia), which include premature atrial contractions (PACs), paroxysmal supraventricular tachycardia (PSVT), accessory pathway tachycardias, such as Wolff-Parkinson-White (WPW) syndrome, atrial tachycardia, atrial fibrillation (AF), and atrial flutter.
Ventricular tachycardia is a heart rhythm issue (arrhythmia) brought on by erratic electrical signals in the lower chambers of the heart (ventricles). Other names for this condition are VT and V-tach. At rest, a healthy heart normally beats 60 to 100 times per minute. The heart beats more quickly in ventricular tachycardia, typically 100 or more beats per minute or more. Types of ventricular arrhythmias include premature ventricular contractions (PVCs), ventricular tachycardia (V-tach), ventricular fibrillation (V-fib), and long QT.
Antiarrhythmics are drugs that both prevent and cure an abnormally rapid or irregular heartbeat. They can lessen symptoms and assist in preventing potentially fatal consequences. Some of these medications block erratic, excessive electrical impulses. Others prevent accelerated impulses from moving through the heart's tissues. Most antiarrhythmic drugs are designed for long-term usage.
[4093637]
Global Critical Care Antiarrhythmic Drugs Market Dynamics
Rising prevalence of cardiovascular diseases globally is the major driving factor for the critical care antiarrhythmic drugs market revenue growth. AF is one of the key causes of irregular heartbeats. Increasing prevalence of the condition is expected to drive the critical care antiarrhythmic drugs market expansion. Moreover, increasing usage of antiarrhythmic drugs in intensive care units in the treatment of individuals with acute arrhythmias is promoting the revenue growth of the critical care antiarrhythmic drugs market.
Rise in the number of clinical trials for antiarrhythmic drugs is expected to boost the revenue growth in the critical care antiarrhythmic drugs market during the forecast period. Obesity and lack of physical activity may contribute to increase in the risk of heart disease. Moreover, growing geriatric population and availability of oral drugs for the treatment of arrhythmias are supporting the revenue growth of the critical care antiarrhythmic drugs market.
However, various side effects associated with antiarrhythmic drugs, such as constipation, dizziness, and excessive thirst, are likely to hamper the revenue growth of the critical care antiarrhythmic drugs market in the next few years.
Global Critical Care Antiarrhythmic Drugs Market Ecosystem
The global critical care antiarrhythmic drugs market is analyzed from three perspectives: drug class, disease type, and region.
Critical Care Antiarrhythmic Drugs Market by Drug Class
Based on the drug class, the global critical care antiarrhythmic drugs market is segmented into beta blockers, calcium channel blockers, sodium channel blockers, potassium channel blockers, and others.
The beta blockers segment dominates the critical care antiarrhythmic drugs market. Increase in the usage of beta blockers to manage abnormal heart rhythm in individuals with AF is one of the reasons boosting revenue growth in the segment. Beta-blocker drugs are used to reduce heart rate, frequently by preventing hormones, such as adrenaline, which reduces the possibility of a heart attack. Moreover, rise in the number of clinical trials to study the effect of beta blockers in the treatment of arrhythmia is fueling the segment revenue growth.
Critical Care Antiarrhythmic Drugs Market by Disease Type
[273829]
Based on the disease type, the global critical care antiarrhythmic drugs market is segmented into supraventricular arrhythmias, ventricular arrhythmias, and others.
The supraventricular arrhythmias segment accounts for the largest revenue share of the critical care antiarrhythmic drugs market. The dominating revenue share of the supraventricular arrhythmias segment can be attributed to rising prevalence of AF, which is the most frequent kind of arrhythmia. Additionally, the segment is expanding significantly due to increasing elderly population, who are at higher risk of AF. In addition, prevalence of AF is rising due to increased usage of alcohol & cigarette and a lack of physical activity among people from developed and developing countries. These factors are further fueling the segment's growth.
Critical Care Antiarrhythmic Drugs Market by Region
Based on the region, the global critical care antiarrhythmic drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world (RoW).
North America dominated the global critical care antiarrhythmic drugs market with the largest revenue share, followed by Europe and Asia Pacific. Rising prevalence of cardiovascular disease is driving revenue growth in this region. According to the Centers for Disease Control and Prevention (CDC), heart disease is the leading cause of death in the U.S. Around 697,000 people died in the country due to heart disease in 2020, accounting for 1 of every 5 deaths. Additionally, one of the key factors driving the regional revenue growth is rising number of clinical trials for the development of innovative antiarrhythmic medications, specifically in the U.S. The presence of well-developed healthcare infrastructure and rise in overall healthcare expenditure are also contributing to the revenue growth in this region. Moreover, the presence of major players and increase in awareness regarding the medications related to arrhythmias are expected to boost the revenue growth in this region during the forecast period.
Global Critical Care Antiarrhythmic Drugs Market Competitive Landscape
The prominent players operating in the critical care antiarrhythmic drugs market are:
Global Critical Care Antiarrhythmic Drugs Market Strategic Developments
Antiarrhythmics are drugs that both prevent and cure an abnormally rapid or irregular heartbeat. They can lessen symptoms and assist in preventing potentially fatal consequences. Some of these medications block erratic, excessive electrical impulses.
The beta blockers segment accounts for the largest revenue share of the critical care antiarrhythmic drugs market.
The global critical care antiarrhythmic drugs market was valued at US$ 958 million in 2021.
Pfizer Inc., Bayer AG, Baxter International Inc., Novartis AG, Mylan N.V., and Sanofi S.A are among the major players operating in the critical care antiarrhythmic drugs market.
North America is the key revenue growth region of the global critical care antiarrhythmic drugs market.
* Insights on financial performance are subject to the availability of information in the public domain